Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31351901 | 0.83 | CYP1A2 (0.56) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL561213 | 0.83 | CYP1A2 (0.56) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL13490745 | 0.83 | L3MBTL1 (0.70) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL6043540 | 0.81 | L3MBTL1 (0.50) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL3083050 | 0.81 | L3MBTL1 (0.50) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL31351899 | 0.81 | CYP1A2 (0.50) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL2806322 | 0.81 | L3MBTL1 (0.50) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL3223100 | 0.81 | MAPT (0.39) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL31351903 | 0.81 | L3MBTL1 (0.52) | L3MBTL1MAPTHPGDATMNPSR1 | |
| SCHEMBL4171112 | 0.81 | L3MBTL1 (0.52) | L3MBTL1MAPTHPGDATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| EP-1689712-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | L3MBTL1 4109/4885MAPT 1266/4885HPGD 113/4885 |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | L3MBTL1 4360/4885MAPT 731/4885HPGD 230/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | L3MBTL1 4274/4885MAPT 625/4885HPGD 232/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | L3MBTL1 4274/4885MAPT 625/4885HPGD 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.